| 21005 |
Autologous anti-CD19-transduced CD3+ cells |
Tecartus® |
For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor. |
Rapid Review Complete |
17th July 2023 |
 |
| 23037 |
Beclometasone /formoterol |
Fostair® |
Beclometasone / formoterol (Fostair®) for COPD. HTA ID 23037 Symptomatic treatment of patients with severe chronic obstructive pulmonary disease [COPD] (forced expiratory volume [FEV1] <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. |
Rapid Review Complete |
20th July 2023 |
|
| 23033 |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide |
Trimbow® |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disorder (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA). |
Rapid Review Complete |
19th July 2023 |
|
| 23034 |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide |
Trimbow® |
Beclometasone dipropionate anhydrous + formoterol fumarate dihydrate + glycopyrronium bromide (Trimbow®) for the maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and a medium or high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year |
Rapid Review Complete |
19th July 2023 |
|
| 23038 |
Beclometasone/formoterol |
Fostair® |
Beclometasone/formoterol (Fostair®) is indicated for the regular treatment of asthma where use of a combination product (inhaled corticosteroid [ICS] and long-acting beta2-agonist [LABA]) is appropriate: -in patients not adequately controlled with ICS and 'as needed' inhaled rapid-acting beta2-agonist; or -in patients already adequately controlled on both ICS and LABA. |
Rapid Review Complete |
20th July 2023 |
|
| 21052 |
Bimekizumab |
Bimzelx® |
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. |
Rapid Review complete |
6th July 2023 |
|
| 21025 |
Cenobamate |
Ontozry® |
Adjunctive treatment of focal onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 22073 |
Drospirenone/estetrol monohydrate |
Drovelis® |
Drospirenone/estetrol monohydrate is indicated for oral contraception. |
Rapid Review Complete |
6th July 2023 |
|
| 23031 |
Itopride Hydrochloride |
Progit® |
Treatment of gastrointestinal symptoms of functional dyspepsia caused by reduced gastrointestinal motility. |
Rapid Review Complete |
7th July 2023 |
|
| 19050 |
Larotrectinib |
Vitrakvi® |
For patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 20061 |
Mogamulizumab |
Poteligeo® |
For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 21049 |
Nivolumab |
Opdivo® |
Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5. |
NCPE Assessment Process Complete |
11th July 2023 |
|
| 21023 |
Nivolumab |
Opdivo® |
Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine-based combination chemotherapy. |
NCPE Assessment Process Complete |
6th July 2023 |
|
| 21032 |
Pembrolizumab |
Keytruda® |
In combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS≥10. |
NCPE Assessment Process Complete |
6th July 2023 |
|
